Loading...
The Global Landscape of Genetic Variation in Parkinson's disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance
Зохиогч
Lange, Lara M
Fang, Zih-Hua
Makarious, Mary B
Kuznetsov, Nicole
Brolin, Kajsa Atterling
Ballard, Shannon
Bardien, Soraya
Doquenia, Maria Leila
Heutink, Peter
Houlden, Henry
Iwaki, Hirotaka
Jasaityte, Simona
Jones, Lietsel
Junker, Johanna
Kaiyrzhanov, Rauan
Koretsky, Mathew J
Kumar, Kishore R
Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD)
Leonard, Hampton L
Levine, Kristin S
Lim, Shen-Yang
Mencacci, Niccoló E
Mohamed, Wael M Y
Nalls, Mike A
Noyce, Alastair J
Ojha, Rajeev
Okubadejo, Njideka U
Rehman, Shoaib Ur
Screven, Laurel
Shashkin, Chingiz
Sopromadze, Sophia
Stafford, Eleanor J
Tan, Ai Huey
Tan, Manuela
Tavadyan, Zaruhi
Trinh, Joanne
Valente, Enza Maria
Vitale, Dan
Zharkinbekova, Nazira
Lohmann, Katja
Bandres-Ciga, Sara
Blauwendraat, Cornelis
Singleton, Andrew
Morris, Huw R
Klein, Christine
Global Parkinson’s Genetics Program (GP2)
Он
2025 оны долоодугаар сар
Төрөл
journal article
Journal
medRxiv : the preprint server for health sciences
Хураангуй
BACKGROUND: The genetic architecture of Parkinson's disease (PD) varies considerably across ancestries, yet most genetic studies have focused on individuals of European descent, limiting our insights into the genetic architecture of PD at a global scale.
METHODS: We conducted a large-scale, multi-ancestry investigation of causal and risk variants in PD-related genes. Using genetic datasets from the Global Parkinson's Genetics Program, we analyzed sequencing and genotyping data from 69,881 individuals, including 41,139 affected and 28,742 unaffected, from eleven different ancestries, including ~30% of individuals from non-European ancestries. FINDINGS: Our findings revealed shared and ancestry-specific patterns in the prevalence and spectrum of PD-associated variants. Overall, ~2% of affected individuals carried a causative variant, with substantial variations across ancestries ranging from <0·5% in African, African-admixed, and Central Asian to >10% in Middle Eastern and Ashkenazi Jewish ancestries. Including disease-associated GBA1 and LRRK2 risk variants raised the yield to ~12.5%, largely driven by GBA1, except in East Asians, where LRRK2 risk variants dominated. GBA1 variants were most frequent globally, albeit with substantial differences in frequencies and variant spectra. While GBA1 variants were identified across all ancestries, frequencies ranged from 3·4% in Middle Eastern to 51·7% in African ancestry. Similarly, LRRK2 variants showed ancestry-specific enrichment, with G2019S most frequently seen in Middle Eastern and Ashkenazi Jewish, and risk variants predominating in East Asians. However, clinical trials targeting proteins encoded by these genes are primarily based in Europe and North America. INTERPRETATION: This large-scale, multi-ancestry assessment offers crucial insights into the population-specific genetic architecture of PD. It underscores the critical need for increased diversity in PD genetic research to improve diagnostic accuracy, enhance our understanding of disease mechanisms across populations, and ensure the equitable development and application of emerging precision therapies.
METHODS: We conducted a large-scale, multi-ancestry investigation of causal and risk variants in PD-related genes. Using genetic datasets from the Global Parkinson's Genetics Program, we analyzed sequencing and genotyping data from 69,881 individuals, including 41,139 affected and 28,742 unaffected, from eleven different ancestries, including ~30% of individuals from non-European ancestries. FINDINGS: Our findings revealed shared and ancestry-specific patterns in the prevalence and spectrum of PD-associated variants. Overall, ~2% of affected individuals carried a causative variant, with substantial variations across ancestries ranging from <0·5% in African, African-admixed, and Central Asian to >10% in Middle Eastern and Ashkenazi Jewish ancestries. Including disease-associated GBA1 and LRRK2 risk variants raised the yield to ~12.5%, largely driven by GBA1, except in East Asians, where LRRK2 risk variants dominated. GBA1 variants were most frequent globally, albeit with substantial differences in frequencies and variant spectra. While GBA1 variants were identified across all ancestries, frequencies ranged from 3·4% in Middle Eastern to 51·7% in African ancestry. Similarly, LRRK2 variants showed ancestry-specific enrichment, with G2019S most frequently seen in Middle Eastern and Ashkenazi Jewish, and risk variants predominating in East Asians. However, clinical trials targeting proteins encoded by these genes are primarily based in Europe and North America. INTERPRETATION: This large-scale, multi-ancestry assessment offers crucial insights into the population-specific genetic architecture of PD. It underscores the critical need for increased diversity in PD genetic research to improve diagnostic accuracy, enhance our understanding of disease mechanisms across populations, and ensure the equitable development and application of emerging precision therapies.
